{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:26:55Z","timestamp":1794634015688,"version":"4.9.1"},"reference-count":71,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>T-cell dysfunction is an important contributor to both multiple myeloma (MM) disease progression and failure of antimyeloma chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (TCE) therapies. Overcoming T-cell dysfunction is therefore key to improving outcomes of patients with MM. Immunomodulatory drugs and cereblon E3 ligase modulatory drugs have been observed to activate T cells and, more recently, reduce T-cell dysfunction; however, the underlying mechanisms behind this are incompletely understood. Here, using bone marrow samples from patients with MM, we demonstrate a significant reduction in dysfunctional T-cell populations expressing exhaustion markers, such as TIGIT, upon treatment with mezigdomide. We further demonstrate the ability of mezigdomide to improve T-cell function and cytotoxicity in primary T-cell models of T-cell dysfunction and bispecific TCE therapy in vitro. Using concurrent assay for transposase-accessible chromatin using sequencing, chromatin immunoprecipitation sequencing, high-throughput chromatin conformation capture, and RNA sequencing in primary T cells treated with mezigdomide, we demonstrate the novel role of transcription factor Ikaros in regulating an important T-cell exhaustion gene TIGIT. Finally, we demonstrate the ability of mezigdomide to enhance survival outcomes of anti\u2013B-cell maturation antigen CAR-T therapy in vivo. Overall, our data show that mezigdomide treatment improves antimyeloma T-cell therapy efficacy and reduces T-cell dysfunction by abrogating Ikaros-mediated upregulation of exhaustion genes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030891","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:42:13Z","timestamp":1778578933000},"page":"1129-1142","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0380-7112","authenticated-orcid":false,"given":"Lucia Y.","family":"Chen","sequence":"first","affiliation":[{"name":"1MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"2Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8884-2100","authenticated-orcid":false,"given":"Adolfo","family":"Aleman","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Larrayoz","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Center for Applied Medical Research, Clinica University of Navarra Cancer Center, University of Navarra, Navarra Institute for Health Research, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiling","family":"Chiu","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfei","family":"Zhao","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Kelly","sequence":"additional","affiliation":[{"name":"6Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0192-4400","authenticated-orcid":false,"given":"Seunghee","family":"Kim-Schulz","sequence":"additional","affiliation":[{"name":"6Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-0564","authenticated-orcid":false,"given":"Alessandro","family":"Lagana","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1690-8035","authenticated-orcid":false,"given":"Tracy T.","family":"Chow","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7122-5475","authenticated-orcid":false,"given":"Teresa","family":"Lozano","sequence":"additional","affiliation":[{"name":"7Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Navarra Institute for Health Research, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1641-3881","authenticated-orcid":false,"given":"Juan J.","family":"Lasarte","sequence":"additional","affiliation":[{"name":"7Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Navarra Institute for Health Research, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hamley","sequence":"additional","affiliation":[{"name":"1MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Baker","sequence":"additional","affiliation":[{"name":"8Oxford Translational Myeloma Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5451","authenticated-orcid":false,"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Oppermann","sequence":"additional","affiliation":[{"name":"8Oxford Translational Myeloma Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amatangelo","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5512-1625","authenticated-orcid":false,"given":"Anita K.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Hagner","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Martinez-Climent","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Center for Applied Medical Research, Clinica University of Navarra Cancer Center, University of Navarra, Navarra Institute for Health Research, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-7043","authenticated-orcid":false,"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[{"name":"1MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"},{"name":"2Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"},{"name":"8Oxford Translational Myeloma Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0413-4271","authenticated-orcid":false,"given":"Thomas A.","family":"Milne","sequence":"additional","affiliation":[{"name":"1MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026101910512631300_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026101910512631300_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2026101910512631300_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41525-022-00340-x","article-title":"Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma","volume":"8","author":"Pilcher","year":"2023","journal-title":"Npj Genom Med"},{"issue":"1","key":"2026101910512631300_bib4","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1038\/s41467-023-41562-6","article-title":"Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance","volume":"14","author":"Botta","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"2026101910512631300_bib5","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026101910512631300_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood-2024-203306","article-title":"Tumour-intrinsic features shape T-cell differentiation through myeloma disease evolution","volume":"144","author":"Foster","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026101910512631300_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"4","key":"2026101910512631300_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2026101910512631300_bib9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026101910512631300_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2026101910512631300_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med Overseas Ed"},{"issue":"24","key":"2026101910512631300_bib12","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026101910512631300_bib13","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026101910512631300_bib14","doi-asserted-by":"crossref","first-page":"568056","DOI":"10.3389\/fonc.2020.568056","article-title":"Altered T-lymphocyte biology following high-dose melphalan and autologous stem cell transplantation with implications for adoptive T-cell therapy","volume":"10","author":"Mika","year":"2020","journal-title":"Front Oncol"},{"issue":"19","key":"2026101910512631300_bib15","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2026101910512631300_bib16","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"van de Donk","year":"2024","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2026101910512631300_bib17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2024-203007","article-title":"Biological and clinical significance of endogenous and chimeric antigen receptor (CAR) T cell immune profiling in relapsed\/refractory multiple myeloma (RRMM) patients [abstract]","volume":"144","author":"Paiva","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101910512631300_bib18","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2024-205126","article-title":"The potential mechanisms of relapse in multiple myeloma following anti-BCMA CAR-T therapy and a promising target for improving CAR-T efficacy [abstract]","volume":"144","author":"Xia","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026101910512631300_bib19","first-page":"191","article-title":"PD1+TIGIT+2B4+KLRG1+ cells might underlie T cell dysfunction in patients treated with BCMA-directed chimeric antigen receptor T cell therapy","volume":"30","author":"Mishra","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"13","key":"2026101910512631300_bib20","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026101910512631300_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"14","key":"2026101910512631300_bib22","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell\u2013redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2026101910512631300_bib23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional hyper-expanded clonotypes and lack of TCR clonal replacement predict resistance to T cell engagers in multiple myeloma","volume":"140","author":"Neri","year":"2022","journal-title":"Blood"},{"issue":"5971","key":"2026101910512631300_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"6168","key":"2026101910512631300_bib25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"2026101910512631300_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"3","key":"2026101910512631300_bib27","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2026101910512631300_bib28","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101910512631300_bib29","doi-asserted-by":"crossref","first-page":"I107","DOI":"10.1136\/ard.58.2008.i107","article-title":"Immunomodulation by thalidomide and thalidomide analogues","volume":"58","author":"Corral","year":"1999","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2026101910512631300_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1089\/jir.2005.25.604","article-title":"Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT","volume":"25","author":"Payvandi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"2026101910512631300_bib31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2026101910512631300_bib32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"issue":"13","key":"2026101910512631300_bib33","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"issue":"11","key":"2026101910512631300_bib34","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026101910512631300_bib35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026101910512631300_bib36","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood-2024-201186","article-title":"Improving anti-BCMA CAR-T functionality with novel celmods in multiple myeloma","volume":"144","author":"Aleman","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026101910512631300_bib37","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1182\/blood-2023-174253","article-title":"Early intervention with celmods, but not imids, prevents relapse to forimtamig driven by GPRC5D-negative myeloma cells","volume":"142","author":"Eckmann","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"2026101910512631300_bib38","doi-asserted-by":"crossref","first-page":"e805462a","DOI":"10.1097\/01.HS9.0000970100.80546.2a","article-title":"Synergistic antitumor activity of the BCMA 2 + 1 T cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and celmod agents in multiple myeloma (MM) preclinical models [abstract]","volume":"7","author":"Paiva","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"2026101910512631300_bib39","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1535-7163.MCT-22-0498","article-title":"IMiDs augment CD3-bispecific antibody\u2013induced CD8+ T-cell cytotoxicity and expansion by enhancing IL2 production","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2026101910512631300_bib40","doi-asserted-by":"crossref","first-page":"101584","DOI":"10.1016\/j.xcrm.2024.101584","article-title":"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep Med"},{"issue":"6","key":"2026101910512631300_bib41","doi-asserted-by":"crossref","first-page":"101571","DOI":"10.1016\/j.xcrm.2024.101571","article-title":"Pharmacodynamic changes in tumor and immune cells drive iberdomide\u2019s clinical mechanisms of activity in relapsed and refractory multiple myeloma","volume":"5","author":"Amatangelo","year":"2024","journal-title":"Cell Rep Med"},{"issue":"7","key":"2026101910512631300_bib42","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2006-07-037754","article-title":"Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells","volume":"109","author":"Bandyopadhyay","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2026101910512631300_bib43","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.4049\/jimmunol.0901284","article-title":"Ikaros is a regulator of Il10 expression in CD4+ T cells","volume":"183","author":"Umetsu","year":"2009","journal-title":"J Immunol"},{"issue":"17","key":"2026101910512631300_bib44","doi-asserted-by":"crossref","first-page":"e2023172118","DOI":"10.1073\/pnas.2023172118","article-title":"CD4+ T cells require Ikaros to inhibit their differentiation toward a pathogenic cell fate","volume":"118","author":"Bernardi","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5083","key":"2026101910512631300_bib45","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.1439790","article-title":"Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment","volume":"258","author":"Georgopoulos","year":"1992","journal-title":"Science"},{"issue":"1","key":"2026101910512631300_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.immunol.15.1.155","article-title":"The role of the Ikaros gene in lymphocyte development and homeostasis","volume":"15","author":"Georgopoulos","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2026101910512631300_bib47","first-page":"101804","article-title":"Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay","volume":"5","author":"Tay","year":"2024","journal-title":"CR Med"},{"issue":"7990","key":"2026101910512631300_bib48","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-023-06733-x","article-title":"Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer","volume":"624","author":"Zhou","year":"2023","journal-title":"Nature"},{"issue":"1","key":"2026101910512631300_bib49","first-page":"Unit10.17","article-title":"Web-based analysis and publication of flow cytometry experiments","volume":"Chapter 10","author":"Kotecha","year":"2010","journal-title":"Curr Protoc Cytom"},{"issue":"12","key":"2026101910512631300_bib50","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nmeth.2688","article-title":"Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position","volume":"10","author":"Buenrostro","year":"2013","journal-title":"Nat Methods"},{"issue":"24","key":"2026101910512631300_bib51","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2024027496","article-title":"Reprogramming glutamine metabolism enhances BCMA-CAR T-cell fitness and therapeutic efficacy in multiple myeloma","volume":"146","author":"Navarro","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026101910512631300_bib52","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"14","key":"2026101910512631300_bib53","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026101910512631300_bib54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s42003-019-0415-5","article-title":"diffcyt: differential discovery in high-dimensional cytometry via high-resolution clustering","volume":"2","author":"Weber","year":"2019","journal-title":"Commun Biol"},{"issue":"41","key":"2026101910512631300_bib55","doi-asserted-by":"crossref","first-page":"30227","DOI":"10.1074\/jbc.M702541200","article-title":"Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes","volume":"282","author":"Sridharan","year":"2007","journal-title":"J Biol Chem"},{"issue":"88","key":"2026101910512631300_bib56","doi-asserted-by":"crossref","first-page":"eabq3109","DOI":"10.1126\/sciimmunol.abq3109","article-title":"Ikaros is a principal regulator of Aire+ mTEC homeostasis, thymic mimetic cell diversity, and central tolerance","volume":"8","author":"Sin","year":"2023","journal-title":"Sci Immunol"},{"issue":"1","key":"2026101910512631300_bib57","doi-asserted-by":"crossref","first-page":"8823","DOI":"10.1038\/ncomms9823","article-title":"Ikaros mediates gene silencing in T cells through Polycomb repressive complex 2","volume":"6","author":"Oravecz","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"2026101910512631300_bib58","doi-asserted-by":"crossref","first-page":"e57435","DOI":"10.1371\/journal.pone.0057435","article-title":"The Ikaros transcription factor regulates responsiveness to IL-12 and expression of IL-2 receptor alpha in mature, activated CD8 T cells","volume":"8","author":"Clambey","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"2026101910512631300_bib59","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.4049\/jimmunol.1801270","article-title":"Lack of Ikaros deregulates inflammatory gene programs in T cells","volume":"202","author":"Lyon De Ana","year":"2019","journal-title":"J Immunol"},{"issue":"9","key":"2026101910512631300_bib71","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.2025030873","article-title":"Mezigdomide reverses T-cell exhaustion through degradation of IKZF1\/IKZF3 and reinvigoration of cytokine production pathways","volume":"148","author":"Chiu","year":"2026","journal-title":"Blood"},{"issue":"1","key":"2026101910512631300_bib60","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.bneo.2025.100179","article-title":"Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma","volume":"3","author":"Bjorklund","year":"2026","journal-title":"Blood Neoplasia"},{"issue":"3","key":"2026101910512631300_bib61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2026101910512631300_bib62","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","article-title":"Cutting edge: TIGIT has T cell-intrinsic inhibitory functions","volume":"186","author":"Joller","year":"2011","journal-title":"J Immunol"},{"issue":"6414","key":"2026101910512631300_bib63","doi-asserted-by":"crossref","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","article-title":"Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"issue":"1","key":"2026101910512631300_bib64","doi-asserted-by":"crossref","first-page":"15398","DOI":"10.1038\/ncomms15398","article-title":"pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase","volume":"8","author":"An","year":"2017","journal-title":"Nat Commun"},{"issue":"16","key":"2026101910512631300_bib65","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2026101910512631300_bib66","doi-asserted-by":"crossref","first-page":"e157907","DOI":"10.1172\/JCI157907","article-title":"TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice","volume":"133","author":"Minnie","year":"2023","journal-title":"J Clin Invest"},{"issue":"16","key":"2026101910512631300_bib67","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2026101910512631300_bib68","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s43018-024-00818-w","article-title":"Clinical response and pathway-specific correlates following TIGIT\/Lag-3-blockade in myeloma","volume":"5","author":"Richard","year":"2024","journal-title":"Nat Cancer"},{"key":"2026101910512631300_bib69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2021.10.016","article-title":"IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors","volume":"524","author":"Zou","year":"2022","journal-title":"Cancer Lett"},{"issue":"3","key":"2026101910512631300_bib70","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/9\/1129\/2541627\/blood_bld-2025-030891-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/9\/1129\/2541627\/blood_bld-2025-030891-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:51:39Z","timestamp":1792421499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/9\/1129\/568277\/Ikaros-degradation-by-mezigdomide-reduces-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030891","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,27]]},"published":{"date-parts":[[2026,8,27]]}}}